The stock of Regeneron Pharmaceuticals, Inc (REGN) has gone down by -4.42% for the week, with a -4.88% drop in the past month and a -38.15% drop in the past quarter. The volatility ratio for the week is 2.97%, and the volatility levels for the past 30 days are 2.63% for REGN. The simple moving average for the past 20 days is -5.58% for REGN’s stock, with a -27.90% simple moving average for the past 200 days.
Is It Worth Investing in Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) Right Now?
Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) has a price-to-earnings ratio that is above its average at 17.53x. The stock has a 36-month beta value of 0.09. Opinions on the stock are mixed, with 11 analysts rating it as a “buy,” 6 as “overweight,” 7 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for REGN is 105.92M, and at present, short sellers hold a 1.70% of that float. On December 20, 2024, the average trading volume of REGN was 827.65K shares.
REGN) stock’s latest price update
The stock price of Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) has plunged by -0.89 when compared to previous closing price of 714.62, but the company has seen a -4.42% decline in its stock price over the last five trading sessions. globenewswire.com reported 2024-12-19 that Investigational REGN7508 (catalytic domain) and REGN9933 (A2 domain) are being evaluated for their potential to control thrombosis while minimizing bleeding risk in a variety of patient populations and clinical settings
Analysts’ Opinion of REGN
Many brokerage firms have already submitted their reports for REGN stocks, with BofA Securities repeating the rating for REGN by listing it as a “Underperform.” The predicted price for REGN in the upcoming period, according to BofA Securities is $565 based on the research report published on December 10, 2024 of the current year 2024.
Wolfe Research, on the other hand, stated in their research note that they expect to see REGN reach a price target of $1150. The rating they have provided for REGN stocks is “Outperform” according to the report published on November 15th, 2024.
Citigroup gave a rating of “Neutral” to REGN, setting the target price at $895 in the report published on November 14th of the current year.
REGN Trading at -14.89% from the 50-Day Moving Average
After a stumble in the market that brought REGN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -41.52% of loss for the given period.
Volatility was left at 2.63%, however, over the last 30 days, the volatility rate increased by 2.97%, as shares sank -4.72% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -30.03% lower at present.
During the last 5 trading sessions, REGN fell by -4.42%, which changed the moving average for the period of 200-days by -27.14% in comparison to the 20-day moving average, which settled at $750.09. In addition, Regeneron Pharmaceuticals, Inc saw -19.36% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at REGN starting from McCourt Marion, who sale 1,000 shares at the price of $844.61 back on Nov 01 ’24. After this action, McCourt Marion now owns 12,931 shares of Regeneron Pharmaceuticals, Inc, valued at $844,610 using the latest closing price.
MARION E MCCOURT, the Officer of Regeneron Pharmaceuticals, Inc, proposed sale 1,000 shares at $844.61 during a trade that took place back on Nov 01 ’24, which means that MARION E MCCOURT is holding shares at $844,610 based on the most recent closing price.
Stock Fundamentals for REGN
Current profitability levels for the company are sitting at:
- 0.29 for the present operating margin
- 0.84 for the gross margin
The net margin for Regeneron Pharmaceuticals, Inc stands at 0.34. The total capital return value is set at 0.12. Equity return is now at value 17.17, with 13.37 for asset returns.
Based on Regeneron Pharmaceuticals, Inc (REGN), the company’s capital structure generated 0.06 points at debt to capital in total, while cash flow to debt ratio is standing at 2.14. The debt to equity ratio resting at 0.07. The interest coverage ratio of the stock is 63.56.
Currently, EBITDA for the company is 4.69 billion with net debt to EBITDA at 0.14. When we switch over and look at the enterprise to sales, we see a ratio of 5.58. The receivables turnover for the company is 2.27for trailing twelve months and the total asset turnover is 0.37. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.28.
Conclusion
To sum up, Regeneron Pharmaceuticals, Inc (REGN) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
